title: Synthesis and pharmacology of site specific cocaine abuse treatment agents: a new synthetic methodology for methylphenidate analogs based on the Blaise reaction.
abstract: In order to make new analogs of the dopamine (DA) uptake inhibitor methylphenidate, a synthetic methodology based on the Blaise reaction was developed. The reaction between alpha-bromophenylacetic acid esters, zinc and alpha-cyano-omega-mesylates gave stable primary enamines. After reduction of the enamines with cyanoborohydride, the amines could be cyclized to methylphenidate analogs in which the amine ring size and aromatic ring were varied. These compounds were tested for inhibitory potency against [(3)H]WIN 35,428 binding to the cocaine recognition site and [(3)H]DA uptake using rat striatal tissue. When the heterocyclic ring size was varied, the six-membered ring of methylphenidate appeared to be the optimum ring size. When the aryl ring was varied the 4-trifluoromethylphenyl analog was less potent than methylphenidate, the beta-naphthyl congener was considerably more potent, whereas the alpha-naphthyl congener was less potent. Most of the compounds tested had ratios of uptake to binding inhibition (discrimination ratio) that were similar to cocaine and were therefore not lead compounds for the development of cocaine antagonists.
authors.affiliation: School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332-0400, USA. howard.deutsch@chemistry.gatech.edu
authors.forename: H M
authors.initials: HM
authors.lastname: Deutsch
authors.forename: X
authors.initials: X
authors.lastname: Ye
authors.forename: Q
authors.initials: Q
authors.lastname: Shi
authors.forename: Z
authors.initials: Z
authors.lastname: Liu
authors.forename: M M
authors.initials: MM
authors.lastname: Schweri
mesh_terms: D000818:Animals; D001671:Biochemistry / Q000379:methods; D003042:Cocaine / Q000031:analogs & derivatives* / Q000378:metabolism; D019970:Cocaine-Related Disorders / Q000188:drug therapy; D004298:Dopamine / Q000378:metabolism; D018765:Dopamine Uptake Inhibitors / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology*; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006801:Humans; D020128:Inhibitory Concentration 50; D009682:Magnetic Resonance Spectroscopy; D008774:Methylphenidate / Q000737:chemistry* / Q000494:pharmacology; D015394:Molecular Structure; D051381:Rats; D013329:Structure-Activity Relationship
chemical_list: D018765:Dopamine Uptake Inhibitors; D008774:Methylphenidate; C021279:(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester; D003042:Cocaine; D004298:Dopamine